Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Blisibimod> ?p ?o }
Showing triples 1 to 67 of
67
with 100 triples per page.
- Blisibimod abstract "Blisibimod (also known as A-623, formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. It is currently under active investigation in clinical trials.".
- Blisibimod atcPrefix "none".
- Blisibimod casNumber "1236126-45-6".
- Blisibimod wikiPageID "32426116".
- Blisibimod wikiPageLength "8530".
- Blisibimod wikiPageOutDegree "25".
- Blisibimod wikiPageRevisionID "691576206".
- Blisibimod wikiPageWikiLink Amgen.
- Blisibimod wikiPageWikiLink Anthera_Pharmaceuticals.
- Blisibimod wikiPageWikiLink Antibody.
- Blisibimod wikiPageWikiLink Atomic_mass_unit.
- Blisibimod wikiPageWikiLink Autoimmune_disease.
- Blisibimod wikiPageWikiLink B-cell_activating_factor.
- Blisibimod wikiPageWikiLink B_cell.
- Blisibimod wikiPageWikiLink Binding_domain.
- Blisibimod wikiPageWikiLink Category:Engineered_proteins.
- Blisibimod wikiPageWikiLink Clinical_trial.
- Blisibimod wikiPageWikiLink Enzyme_inhibitor.
- Blisibimod wikiPageWikiLink Fragment_crystallizable_region.
- Blisibimod wikiPageWikiLink Fusion_protein.
- Blisibimod wikiPageWikiLink Graves_disease.
- Blisibimod wikiPageWikiLink Hashimotos_thyroiditis.
- Blisibimod wikiPageWikiLink IgA_nephropathy.
- Blisibimod wikiPageWikiLink Lupus_nephritis.
- Blisibimod wikiPageWikiLink Multiple_sclerosis.
- Blisibimod wikiPageWikiLink N-terminus.
- Blisibimod wikiPageWikiLink Placebo.
- Blisibimod wikiPageWikiLink Receptor_(biochemistry).
- Blisibimod wikiPageWikiLink Rheumatoid_arthritis.
- Blisibimod wikiPageWikiLink Sjxc3xb6grens_syndrome.
- Blisibimod wikiPageWikiLink Systemic_lupus_erythematosus.
- Blisibimod wikiPageWikiLinkText "Blisibimod".
- Blisibimod atcPrefix "none".
- Blisibimod c "2836".
- Blisibimod casNumber "1236126".
- Blisibimod chemspiderid "none".
- Blisibimod h "4376".
- Blisibimod legalStatus "Investigational".
- Blisibimod molecularWeight "63.6".
- Blisibimod n "756".
- Blisibimod o "858".
- Blisibimod s "26".
- Blisibimod synonyms "A-623".
- Blisibimod verifiedfields "changed".
- Blisibimod verifiedrevid "477373423".
- Blisibimod watchedfields "changed".
- Blisibimod wikiPageUsesTemplate Template:Cascite.
- Blisibimod wikiPageUsesTemplate Template:Chemspidercite.
- Blisibimod wikiPageUsesTemplate Template:Drugbankcite.
- Blisibimod wikiPageUsesTemplate Template:Drugbox.
- Blisibimod wikiPageUsesTemplate Template:Reflist.
- Blisibimod subject Category:Engineered_proteins.
- Blisibimod hypernym Antagonist.
- Blisibimod type ChemicalSubstance.
- Blisibimod type Drug.
- Blisibimod type Chemical.
- Blisibimod type Drug.
- Blisibimod type ChemicalObject.
- Blisibimod type Thing.
- Blisibimod type Q8386.
- Blisibimod comment "Blisibimod (also known as A-623, formerly AMG 623) is a selective antagonist of B-cell activating factor (BAFF, also known as B-lymphocyte stimulator or BLyS), being developed by Anthera Pharmaceuticals as a treatment for systemic lupus erythematosus. It is currently under active investigation in clinical trials.".
- Blisibimod label "Blisibimod".
- Blisibimod sameAs Q4926814.
- Blisibimod sameAs m.0gyrbzj.
- Blisibimod sameAs Q4926814.
- Blisibimod wasDerivedFrom Blisibimod?oldid=691576206.
- Blisibimod isPrimaryTopicOf Blisibimod.